US · KURA
Kura Oncology, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92130
- Website
- kuraoncology.com
Price · as of 2024-12-31
$8.77
Market cap 759.66M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $4.24 | ||||
| 2016 | $8.85 | ||||
| 2017 | $22.90 | ||||
| 2018 | $14.83 | ||||
| 2019 | $11.00 | ||||
| 2020 | $29.50 | ||||
| 2021 | $16.29 | ||||
| 2022 | $10.71 | ||||
| 2023 | $23.53 | ||||
| 2024 | $7.53 |
AI valuation
Our deep-learning model estimates Kura Oncology, Inc.'s (KURA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $8.77
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KURA | Kura Oncology, Inc. | $8.77 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| BCAX | Bicara Therapeutics Inc. … | $16.78 | 919.24M | — | — | — | — | -13.25 | 1.83 | — | -5.00 | -52.99 | 1.83 | 0.00% | — | — | -19.14% | 1967.97% | -16.93% | 0.00 | — | 27.93 | 27.22 | 5.94 | 2500.00% | — | 6190.00% | -8.31% | -4.16 | 1787.22% | 0.00% | 0.00% | 28.78% | -5.00 | -5.50 | — | 6.99 |
| EYPT | EyePoint Pharmaceuticals,… | $17.56 | 1.45B | +9,195% | -75% | — | — | -3.07 | 1.19 | 9.28 | -0.41 | -11.16 | 1.19 | 91.42% | -337.06% | -302.43% | -43.42% | 403.05% | -33.83% | 0.06 | -10418.14 | 7.81 | 7.57 | 0.60 | 2747.00% | -597.00% | 800187.00% | -32.46% | -2.57 | 360.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 1.21 | -0.07 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| PRME | Prime Medicine, Inc. | $4.62 | 833.96M | — | -79% | — | — | -1.45 | 1.86 | 95.42 | -0.69 | — | 1.86 | 100.00% | -6787.36% | -6566.61% | -136.88% | -1418.83% | -79.73% | 0.27 | — | 5.58 | 5.02 | 0.72 | -2417.00% | — | -2525.00% | -45.73% | -3.24 | -912.12% | 0.00% | 0.00% | 39.96% | -0.67 | -1.04 | 45.25 | -3.59 |
| PROK | ProKidney Corp. | $2.24 | 277.76M | — | — | — | — | -0.63 | -0.10 | 1352.79 | 1.59 | -7.18 | -0.10 | 100.00% | -241678.95% | -80507.89% | 15.57% | 13.02% | -37.91% | 0.00 | -20408.44 | 10.93 | 9.96 | 0.60 | 877.00% | — | 2542.00% | -151.60% | -3.49 | 11.09% | 0.00% | 0.00% | 38.56% | 1.37 | 1.62 | -3319.00 | -2.64 |
| REPL | Replimune Group, Inc. | $7.65 | 631.68M | — | — | — | — | -3.38 | 2.01 | — | -1.69 | — | 2.01 | 0.00% | — | — | -62.58% | -1380.14% | -47.60% | 0.18 | -33.15 | 7.95 | 7.82 | 0.14 | -525.00% | — | 409.00% | -23.79% | -3.08 | -1049.44% | 0.00% | 0.00% | 4.35% | -1.64 | -2.15 | — | 0.67 |
| RZLT | Rezolute, Inc. | $3.21 | 307.19M | — | — | — | — | -8.17 | 3.75 | — | -5.53 | — | 3.75 | 0.00% | — | — | -52.56% | 2059.39% | -48.28% | 0.01 | — | 14.37 | 14.09 | 1.16 | -2632.00% | — | 2041.00% | -11.36% | -5.80 | 1780.51% | 0.00% | 0.00% | 4.00% | -5.53 | -6.40 | — | 23.66 |
| SVRA | Savara Inc. | $6.02 | 1.22B | — | — | — | — | -5.37 | 3.01 | — | -3.38 | -11.82 | 3.20 | 0.00% | — | — | -61.50% | -3224.37% | -49.11% | 0.16 | — | 13.73 | 13.40 | -0.11 | 4545.00% | — | 7352.00% | -17.29% | -6.05 | -2784.35% | 0.00% | 0.00% | 0.19% | -3.35 | -3.88 | — | 3.70 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
| TYRA | Tyra Biosciences, Inc. | $33.31 | 1.78B | — | — | — | — | -7.24 | 1.82 | — | -2.80 | — | 1.82 | 0.00% | — | — | -31.60% | -1368.86% | -29.34% | 0.02 | — | 23.81 | 23.53 | 0.83 | -679.00% | — | 3836.00% | -11.25% | -4.78 | -925.54% | 0.00% | 0.00% | 5.54% | -2.79 | -4.13 | — | 17.59 |
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
- CEO
- Troy Edward Wilson
- Employees
- 192
- Beta
- 0.24
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $8.77) − 1 = — (DCF, example).